Eisai lowers Leqembi revenue forecast after rocky entry to market
Eisai has lowered the sales forecast for its Alzheimer’s drug Leqembi (lecanemab), primarily citing delays in revenue in the US.…
As the coronavirus vaccine rolls out across the globe on this page you will find all our latest Covid-19 vaccine updates and live tracking of vaccine development and administration.
You can explore our data and find insights into Covid-19 vaccine clinical trials, country-level vaccination statistics, the impact of vaccination on infection and death rates, and all the latest news and information on the Covid-19 vaccination.
13,411,157,781
+368,349 reported yesterday
5,133,969,263
+118,516 reported yesterday
217
+2 reported yesterday
64.37%
+0% reported yesterday
Public health authorities across the globe have been mobilising to deliver the biggest ever vaccination programme to battle Covid-19. How many people have received the Covid-19 vaccine? We bring you the latest Covid-19 vaccine numbers, including daily Covid-19 vaccine rates per country. Track worldwide Covid-19 vaccine rates with Pharmaceutical Technology and GlobalData.
Some countries have made a fast start with their vaccination efforts. By the end of January, Israel had successfully vaccinated 3 million people with the first dose. While the US may have had a slow start, President Biden has put the vaccination programme at the forefront of his first 100 days agenda.
Country | Doses Administered | Doses per 1000 | Fully Vaccinated Population (%) | Vaccine being used in a country |
---|---|---|---|---|
World | 13,411,157,781 | 1,766.0 | 6760% | |
China | 3,491,077,000 | 2,506.6 | 9167% | CanSino, IMBCAMS, KCONVAC, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001 |
India | 2,206,698,880 | 1,631.4 | 7038% | Corbevax, Covaxin, Novavax, Oxford/AstraZeneca, Sputnik V |
United States | 676,728,782 | 2,068.4 | 7050% | Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech |
Brazil | 486,436,436 | 2,322.2 | 8410% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Indonesia | 444,303,130 | 1,659.9 | 6452% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac |
Japan | 383,747,738 | 3,032.9 | 8170% | Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Bangladesh | 358,785,483 | 2,223.6 | 8708% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac |
Pakistan | 338,642,674 | 1,595.8 | 6617% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Vietnam | 266,266,588 | 2,787.0 | 8993% | Abdala, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Mexico | 225,063,079 | 1,783.5 | 6550% | CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V |
Germany | 192,043,023 | 2,315.8 | 7664% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Valneva |
Russia | 186,692,479 | 1,279.3 | 5462% | EpiVacCorona, Sputnik V |
Philippines | 170,014,442 | 1,594.1 | 6935% | Covaxin, Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Iran | 155,194,752 | 1,847.7 | 6972% | CanSino, Covaxin, COVIran Barekat, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Soberana02, Sputnik Light, Sputnik V |
France | 154,451,978 | 2,305.7 | 7940% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK |
Turkey | 152,543,341 | 1,853.1 | 6460% | Pfizer/BioNTech, Sinovac, Turkovac |
United Kingdom | 151,248,820 | 2,274.8 | 7632% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Italy | 144,574,519 | 2,392.4 | 7937% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK |
Thailand | 142,635,014 | 2,054.4 | 7704% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac |
South Korea | 129,647,782 | 2,510.8 | 8593% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Argentina | 115,694,260 | 2,600.2 | 7839% | CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Egypt | 112,284,725 | 1,097.2 | 4125% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Nigeria | 108,052,995 | 551.6 | 3266% | Oxford/AstraZeneca |
Spain | 105,799,888 | 2,264.4 | 8719% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Canada | 96,956,502 | 2,616.3 | 8571% | Johnson&Johnson, Medicago, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Colombia | 90,210,929 | 1,817.0 | 7442% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Peru | 89,452,255 | 2,796.3 | 8957% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Uzbekistan | 73,580,492 | 2,232.7 | 5422% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik Light, Sputnik V, ZF2001 |
Malaysia | 72,631,041 | 2,253.7 | 8549% | CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac |
Saudi Arabia | 68,534,631 | 2,033.7 | 7547% | Oxford/AstraZeneca, Pfizer/BioNTech |
Taiwan | 67,913,330 | 2,876.4 | 8798% | Medigen, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Myanmar | 64,549,994 | 1,201.9 | 5129% | Oxford/AstraZeneca, Sinopharm/Beijing |
Australia | 63,681,652 | 2,548.0 | 8664% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Chile | 62,688,847 | 3,347.1 | 9451% | CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Nepal | 61,825,430 | 2,201.1 | 8672% | Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Poland | 57,998,335 | 1,527.1 | 5963% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Morocco | 55,388,882 | 1,537.3 | 6529% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Ethiopia | 54,041,862 | 494.8 | 3446% | Covaxin, Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac |
Cambodia | 46,920,796 | 2,887.5 | 9020% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac |
Cuba | 44,415,297 | 3,917.3 | 8833% | Abdala, Soberana Plus, Soberana02 |
Sri Lanka | 40,116,590 | 1,851.3 | 6808% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Ecuador | 39,448,015 | 2,309.0 | 8328% | CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
South Africa | 38,813,021 | 671.7 | 3641% | Johnson&Johnson, Pfizer/BioNTech |
Venezuela | 37,860,994 | 1,311.4 | 5184% | Abdala, Sinopharm/Beijing, Sinovac, Soberana02, Sputnik Light, Sputnik V |
Netherlands | 36,104,942 | 2,095.3 | 6940% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Tanzania | 35,994,687 | 639.1 | 5197% | Johnson&Johnson, Pfizer/BioNTech, Sinopharm/Beijing |
Ukraine | 31,668,577 | 709.7 | 3396% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Belgium | 29,632,916 | 2,594.4 | 8027% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Mozambique | 29,457,535 | 998.7 | 6701% | Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing |
Portugal | 28,167,414 | 2,739.6 | 8655% | Covaxin, Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK, Sinopharm/Beijing, Sinovac |
Uganda | 26,299,538 | 615.6 | 3034% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Sweden | 26,117,645 | 2,564.8 | 7498% | Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Rwanda | 26,106,436 | 2,122.1 | 8046% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V |
Angola | 25,402,678 | 824.5 | 2863% | Oxford/AstraZeneca |
United Arab Emirates | 24,922,054 | 2,530.0 | 9941% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Cote d'Ivoire | 24,277,616 | 968.4 | 4773% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Kenya | 23,132,128 | 450.1 | 2114% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Ghana | 22,384,226 | 752.0 | 3294% | Oxford/AstraZeneca, Sputnik V |
Greece | 22,124,144 | 2,062.3 | 7127% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Kazakhstan | 20,918,681 | 1,144.6 | 5807% | QazVac, Sinopharm/Beijing, Sputnik V |
Hong Kong | 20,804,837 | 2,752.0 | 8995% | Pfizer/BioNTech, Sinovac |
Austria | 20,458,439 | 2,312.5 | 7554% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK, Valneva |
Guatemala | 20,346,236 | 1,179.6 | 4130% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V |
Iraq | 19,557,364 | 508.9 | 2067% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Belarus | 18,871,846 | 1,989.6 | 6758% | KoviVac/Chumakov, Sinopharm/Beijing, Sputnik Light, Sputnik V |
Tajikistan | 18,871,161 | 2,073.6 | 5681% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V |
Israel | 18,649,248 | 2,099.2 | 6934% | Moderna, Pfizer/BioNTech |
Czechia | 18,625,411 | 1,752.9 | 6487% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Honduras | 16,987,951 | 1,771.9 | 6033% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V |
Afghanistan | 16,960,754 | 456.3 | 3796% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Switzerland | 16,939,200 | 1,989.0 | 7061% | Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech |
Romania | 16,827,486 | 864.1 | 4167% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Hungary | 16,701,238 | 1,709.7 | 6354% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Democratic Republic of Congo | 16,398,195 | 195.1 | 1531% | Oxford/AstraZeneca |
Dominican Republic | 16,300,581 | 1,533.9 | 5735% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac |
Nicaragua | 15,328,476 | 2,370.8 | 9421% | Abdala, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Soberana02, Sputnik Light, Sputnik V |
Algeria | 15,267,442 | 361.5 | 1535% | Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V |
Denmark | 15,061,754 | 2,598.0 | 8178% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Singapore | 14,727,569 | 2,611.9 | 9082% | Moderna, Novavax, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac |
Bolivia | 14,690,530 | 1,294.0 | 5426% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Azerbaijan | 13,857,111 | 1,393.7 | 4891% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V |
Sudan | 13,711,970 | 328.0 | 1986% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Zambia | 13,454,213 | 775.4 | 5310% | Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing |
Tunisia | 13,249,161 | 1,145.6 | 5533% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Finland | 13,214,538 | 2,394.8 | 7880% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Costa Rica | 13,148,135 | 2,629.9 | 8696% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Zimbabwe | 12,222,754 | 846.5 | 3291% | Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V |
Norway | 12,145,560 | 2,285.4 | 7630% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
New Zealand | 11,977,450 | 2,451.6 | 8474% | Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
El Salvador | 11,289,175 | 1,758.2 | 6766% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac |
Ireland | 11,122,068 | 2,291.6 | 8371% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Laos | 11,111,066 | 1,527.2 | 7178% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Jordan | 10,057,975 | 1,010.2 | 4578% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Paraguay | 9,646,975 | 1,386.8 | 5096% | Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V |
Somalia | 9,443,849 | 629.2 | 4688% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Uruguay | 9,023,647 | 2,616.1 | 8415% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Panama | 8,869,423 | 2,123.5 | 7598% | Oxford/AstraZeneca, Pfizer/BioNTech |
Guinea | 8,749,048 | 704.8 | 2653% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V |
Serbia | 8,534,688 | 1,222.4 | 4695% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V |
Kuwait | 8,260,050 | 1,996.5 | 8086% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Malawi | 8,114,454 | 447.2 | 2245% | Johnson&Johnson, Oxford/AstraZeneca |
Qatar | 7,609,178 | 2,735.5 | 10253% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Sierra Leone | 7,548,308 | 986.7 | 5636% | Oxford/AstraZeneca, Sinopharm/Beijing |
Niger | 7,187,711 | 320.3 | 2365% | Oxford/AstraZeneca, Sinopharm/Beijing |
Oman | 7,086,050 | 1,467.2 | 6313% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Chad | 6,347,672 | 410.1 | 3929% | Sinopharm/Beijing |
Lebanon | 5,814,699 | 849.0 | 3525% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Mali | 5,793,606 | 303.7 | 1854% | Oxford/AstraZeneca |
Slovakia | 5,754,313 | 1,056.4 | 4733% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V |
Mongolia | 5,492,919 | 1,732.7 | 6863% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Croatia | 5,361,915 | 1,311.2 | 5506% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Burkina Faso | 5,117,982 | 245.6 | 1601% | Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing |
Syria | 5,090,630 | 290.9 | 1348% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Cameroon | 4,735,141 | 187.8 | 1232% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Bulgaria | 4,612,917 | 656.7 | 2958% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Lithuania | 4,546,008 | 1,629.7 | 6741% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Liberia | 4,460,668 | 925.6 | 7742% | Oxford/AstraZeneca |
South Sudan | 4,312,900 | 392.9 | 3845% | Johnson&Johnson, Oxford/AstraZeneca |
Benin | 4,232,541 | 368.5 | 2388% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Mauritania | 4,068,530 | 924.0 | 3493% | Oxford/AstraZeneca, Sinopharm/Beijing |
Palestine | 3,748,571 | 734.8 | 3483% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Libya | 3,739,158 | 559.9 | 1851% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Kyrgyzstan | 3,524,321 | 558.0 | 2198% | Sinopharm/Beijing, Sputnik V |
Bahrain | 3,476,633 | 2,215.2 | 7817% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Togo | 3,398,445 | 430.8 | 1970% | Oxford/AstraZeneca |
Botswana | 3,171,667 | 1,407.0 | 7380% | Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Albania | 3,047,340 | 1,063.1 | 4442% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V |
Slovenia | 2,996,643 | 1,449.5 | 5912% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Madagascar | 2,940,399 | 112.0 | 948% | Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing |
Senegal | 2,936,343 | 185.2 | 910% | Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing |
Georgia | 2,930,677 | 785.5 | 3420% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac |
Latvia | 2,895,716 | 1,503.1 | 6779% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Central African Republic | 2,893,159 | 620.0 | 4857% | Covaxin, Oxford/AstraZeneca |
Mauritius | 2,615,058 | 2,066.7 | 8600% | Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing |
Moldova | 2,276,473 | 642.0 | 3033% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V |
Armenia | 2,150,112 | 728.4 | 3340% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik Light, Sputnik V |
Estonia | 2,112,108 | 1,599.0 | 6523% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Bhutan | 2,011,426 | 2,666.3 | 8983% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Bosnia and Herzegovina | 1,924,950 | 579.1 | 2545% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V |
North Macedonia | 1,862,732 | 894.3 | 4024% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik V |
Kosovo | 1,837,446 | 995.7 | 4471% | Oxford/AstraZeneca, Pfizer/BioNTech |
Macao | 1,801,982 | 2,852.9 | 10166% | Pfizer/BioNTech, Sinopharm/Beijing |
Cyprus | 1,797,542 | 1,419.1 | 5100% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Trinidad and Tobago | 1,580,898 | 1,137.5 | 5158% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Fiji | 1,555,182 | 1,760.3 | 7258% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Jamaica | 1,526,084 | 520.0 | 2586% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Malta | 1,380,907 | 2,855.9 | 9752% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Luxembourg | 1,373,611 | 2,260.2 | 7613% | Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech |
Brunei | 1,291,978 | 2,781.6 | 9616% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Yemen | 1,275,368 | 44.8 | 277% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Lesotho | 1,259,488 | 597.4 | 4392% | Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing |
Namibia | 990,210 | 404.5 | 2201% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Guyana | 953,690 | 1,224.2 | 4880% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Maldives | 951,742 | 1,845.5 | 7469% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V |
Northern Cyprus | 861,519 | 2,312.9 | 8405% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac |
Cape Verde | 859,940 | 1,546.7 | 5553% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Eswatini | 853,821 | 751.5 | 3719% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech |
Comoros | 835,021 | 1,003.2 | 4771% | Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing |
Congo | 833,210 | 9.9 | 78% | Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V |
Gambia | 815,861 | 357.8 | 1567% | Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing |
Guinea-Bissau | 810,299 | 432.3 | 2848% | Oxford/AstraZeneca, Sinopharm/Beijing |
Iceland | 805,469 | 2,278.1 | 8207% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Papua New Guinea | 737,695 | 85.7 | 373% | Oxford/AstraZeneca |
Montenegro | 679,171 | 1,091.3 | 4577% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Solomon Islands | 625,956 | 958.8 | 3896% | Oxford/AstraZeneca |
Gabon | 572,672 | 270.2 | 1214% | Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Haiti | 515,718 | 46.4 | 214% | Johnson&Johnson, Moderna |
Belize | 510,717 | 1,333.2 | 5780% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Suriname | 505,699 | 878.0 | 4130% | Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
French Polynesia | 502,952 | 1,811.3 | 6727% | Johnson&Johnson, Pfizer/BioNTech |
Equatorial Guinea | 488,738 | 373.4 | 1635% | Sinopharm/Beijing, Sinovac |
New Caledonia | 480,702 | 1,649.8 | 6343% | Pfizer/BioNTech |
Samoa | 453,083 | 2,310.1 | 9073% | Oxford/AstraZeneca |
Djibouti | 392,703 | 409.5 | 3668% | CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V |
Barbados | 381,715 | 1,331.7 | 5409% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Vanuatu | 366,638 | 1,252.7 | 5544% | Oxford/AstraZeneca |
Bahamas | 366,083 | 949.3 | 4325% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech |
Sao Tome and Principe | 262,837 | 1,245.5 | 5307% | Oxford/AstraZeneca |
Curacao | 256,029 | 1,601.7 | 6253% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Jersey | 242,600 | 2,250.5 | 7550% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Seychelles | 219,489 | 2,268.3 | 8439% | Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V |
Tonga | 203,208 | 1,922.6 | 7319% | Oxford/AstraZeneca |
Isle of Man | 189,994 | 2,259.8 | 7981% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Guernsey | 178,525 | 2,847.0 | 8406% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Aruba | 174,751 | 1,651.0 | 7965% | Pfizer/BioNTech |
Andorra | 156,242 | 2,029.0 | 6946% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Cayman Islands | 151,822 | 2,365.8 | 9453% | Oxford/AstraZeneca, Pfizer/BioNTech |
Antigua and Barbuda | 136,512 | 1,417.8 | 6479% | Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V |
Gibraltar | 132,810 | 3,938.8 | 12298% | Oxford/AstraZeneca, Pfizer/BioNTech |
Bermuda | 132,042 | 2,064.2 | 7450% | Oxford/AstraZeneca, Pfizer/BioNTech |
Saint Lucia | 122,977 | 676.1 | 3022% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Faeroe Islands | 103,894 | 0% | Moderna, Pfizer/BioNTech | |
Grenada | 90,507 | 812.1 | 3497% | Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Greenland | 79,738 | 1,423.3 | 6874% | Moderna, Pfizer/BioNTech |
Liechtenstein | 74,275 | 1,959.2 | 6980% | Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech |
Turks and Caicos Islands | 73,907 | 1,962.2 | 8153% | Pfizer/BioNTech |
Saint Vincent and the Grenadines | 73,443 | 666.4 | 2870% | Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik Light, Sputnik V |
San Marino | 69,338 | 2,052.3 | 6995% | Pfizer/BioNTech, Sputnik V |
Dominica | 67,647 | 944.5 | 4280% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing |
Monaco | 65,140 | 1,684.0 | 6635% | Pfizer/BioNTech |
Sint Maarten (Dutch part) | 65,095 | 1,601.2 | 6522% | Moderna, Oxford/AstraZeneca, Pfizer/BioNTech |
Saint Kitts and Nevis | 64,297 | 1,208.0 | 5073% | Oxford/AstraZeneca, Pfizer/BioNTech |
Turkmenistan | 41,993 | 7.0 | 16% | EpiVacCorona, Oxford/AstraZeneca, QazVac, Sinopharm/Beijing, Sputnik V, ZF2001 |
Burundi | 37,417 | 3.3 | 31% | Johnson&Johnson, Sinopharm/Beijing |
Bonaire Sint Eustatius and Saba | 35,845 | 1,337.3 | 6244% | Moderna, Pfizer/BioNTech |
Nauru | 32,157 | 2,531.3 | 8931% | Oxford/AstraZeneca |
Tuvalu | 25,591 | 2,171.7 | 7911% | Oxford/AstraZeneca |
Anguilla | 24,474 | 1,354.7 | 5744% | Oxford/AstraZeneca, Pfizer/BioNTech |
Wallis and Futuna | 18,058 | 1,142.3 | 4303% | Moderna |
Saint Helena | 7,892 | 998.6 | 4468% | Oxford/AstraZeneca |
Montserrat | 4,619 | 861.9 | 3642% | Oxford/AstraZeneca |
Falkland Islands | 4,407 | 1,091.1 | 4395% | Oxford/AstraZeneca |
Eritrea | 0 | 0.0 | 0% | |
Marshall Islands | 0 | 0.0 | 0% | |
Timor-Leste | 0 | 0.0 | 0% | |
Micronesia (country) | 0 | 0.0 | 0% | |
Vatican | 0 | 0.0 | 0% |
GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine numbers as they happen each day.
Total doses tracks the number of vaccine doses applied, whether they be the first or second of the two dose treatments or the one dose vaccine. Fully vaccinated captures the combined number of people to have received either both shots of a two-stage vaccine or the one-shot vaccine. See which countries are administering most Covid-19 vaccines and where efforts are falling short.
The first ever dose of Covid-19 vaccine was administered in the UK in December 2020, and the global vaccination effort has fast expanded with most countries beginning to start their vaccination programmes.
However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.
GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine first dose and second dose numbers as they happen each day. See which countries are administering most Covid-19 vaccines and where efforts are falling short.
With the worldwide first dose vaccination administered in the UK in December 2020, the global Covid-19 vaccination effort has fast expanded with most countries beginning to start their vaccination programmes. However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.
This Covid-19 vaccination chart shows a steadily growing Covid-19 vaccination rate globally since January 2021, the first full month of the global Covid-19 vaccination drive. For more details also see GlobalData’s intelligence on Covid-19 vaccinations per country.
With Israel having a head start with Covid-19 vaccine numbers, many countries are stepping up their effort to battle new cases and death rates with fast Covid-19 vaccine roll-outs.
At the start of February nine approved Covid-19 vaccines were being used globally to fight the rising global death rate from Covid-19. The Janssen vaccine is likely to achieve imminent approval and there are almost 50 other Covid-19 vaccines still in development. Some might never progress to regulatory approval, but with new variants of Covid-19 spreading fast the race for the most effective and affordable Covid-19 vaccine is still on. Follow GlobalData’s tracker on Covid-19 vaccine initiatives and Covid-19 vaccine trials here:
Progress: Trial Results expected Awaiting approval Available to public
Trial size Doses requierd Storage temperature Efficacy Number of countries approved
mRNA vaccine, first to demonstrate positive Phase 3 results. Impressive efficacy of 95% in prevention of COVID-19, with a single drawback of requiring unusually cold (-70 degrees F) conditions for storage and transportation in some regions.
Like Pfizer/BioNTech’s offering, is an mRNA vaccine with a nearly identical 95% efficacy for prevention of COVID-19. Also requires freezing temperatures but does not require ultra-low temperatures as Pfizer/BioNTech’s vaccine does.
Adenoviral vaccine which has produced mixed results depending on region, vaccine dosing regimen, schedule and SARS-CoV-2 variant. While overall efficacy may be lower than some competitors, protections against hospitalization and death is strong.
Uses virus-like particles (VLPs) produced in insect cells and demonstrated 100% efficacy against variants "not considered Variants of Concern/Interest" and 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest.
Adenoviral vaccine able to confer nearly 70% protection against all COVID-19 with a single dose. Like AstraZeneca’s vaccine, overall protection is not the highest, but offers near-complete protection against hospitalization and death. Also being tested as a two-dose regimen..
Vaccine from China, one of few vaccines using inactivated SARS-CoV-2 viruses which is a much more conventional vaccine technology than others which have demonstrated positive Phase III data.
Developed by Russia, uses two different adenoviruses, one for each of two doses, as part of a heterologous vaccination plan. Has shown excellent efficacy of just over 90% in preventing all COVID-19.
Like Johnson & Johnson’s vaccine, this vaccine from China showed just under 70% efficacy in preventing all COVID-19 and 90% efficacy in preventing severe COVID-19 with just a single dose.
The second inactivated vaccine, also being developed by China, has shown mixed results in Brazil, where initial efficacy was 86% based on data from the UAE, but efficacy data from Brazil were significantly lower at only 50%.
Adjuvanted inactivated vaccine produced in Vero cells and developed by India, showed 81% efficacy in preventing COVID-19 after two doses.
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V, showed 79.4% efficacy from 28 days after the injection was administered as part of Russia’s mass vaccination program.
ZyCoV-D is the first plasmid DNA, needle-free vaccine against COVID-19, showing 66.6% efficacy after the third injection was administered in over 28,000 volunteers at more than 50 clinical sites spread across India.
CORBEVAX is a recombinant protein sub-unit vaccine, developed from the receptor binding domain (RBD) of the spike protein on the virus’s surface combined with Dynavax’s CpG 1018 adjuvant with alum. It Showed >90% efficacy against Wuhan strain and >80% efficacy against Delta Strain.
VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.
Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern (BA.1). It is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
Comirnaty bivalent Original/Omicron (BA.1) is a bivalent vaccine that contains Comirnaty and a vaccine candidate targeting the Omicron variant of concern (BA.1). It is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
BA.4/.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222 targets the BA.4/.5 subvariants of Omicron. 50 µg booster dose indicated for adults over 18 years of age who have received either a primary series or an initial booster of any of the authorized or approved COVID-19 vaccines. The 50 µg booster dose of mRNA-1273.222 includes 25 µg of mRNA encoding for the spike protein of BA.4/.5 and 25 µg encoding for the original strain of the SARS-CoV-2 virus.
Omicron BA.4/BA.5 Bivalent Vaccine combines 15-µg of mRNA encoding the wild-type spike protein found in the Original Pfizer-BioNTech COVID-19 Vaccine and 15-µg of mRNA encoding the spike protein of the OmicronBA.4/BA.5 subvariants. 30-µg booster dose of Bivalent (Original [15 µg] and Omicron BA.4/BA.5 [15 µg]) approved for individuals ages 12 years and older.
"iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a prefusion stabilized spike protein. It has been specifically formulated to allow intranasal delivery through nasal drops. iNCOVACC received approval under Restricted Use in Emergency Situation for ages 18 and above"
The vaccine is presented in 0.5 mL prefilled syringe, with mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2 as the active substance.
The Indovac vaccine contains the recombinant Receptor-Binding Domain (RBD) protein S of the SARS-Cov-2 virus, is a COVID-19 vaccine with a recombinant protein subunit platform.
The Inavac vaccine is a COVID-19 vaccine with an inactivated virus platform developed by researchers at Airlangga University and produced and registered by PT Biotis Pharmaceuticals Indonesia (PT Biotis).
Coronavirus Disease 2019 (COVID-19) vaccine (Kconvac/ Kconecavac) is a inactivated vaccine composed of SARS-CoV-2 virus antigen
SKYCovione is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for the parental SARS-Cov-2, jointly developed with the Institute for Protein Design (IPD) at the University of Washington School of Medicine with combination of GSK’s pandemic adjuvant.
KoviVac is an inactivated whole-virion concentrated purified coronavirus vaccine
Cov2Bio is a inactivated vaccine composed of SARS-CoV-2 virus antigen
Abdala is a vaccine targeting SARS-CoV-2 virus receptor binding domain recombinant protein
Gemcovac is an in-vitro transcribed self-amplifying mRNA encoding for the S-protein of SARS-CoV-2 vaccine
EpiVacCorona is a synthetic peptide antigen based vaccine . It contains protein S of the SARS-CoV-2 virus, conjugated to the carrier protein
Zifivax is a recombinant protein subunit vaccine composed of new coronavirus spike glycoprotein receptor binding region NCP-RBD protein
V-01 is a recombinant SARS-CoV-2 fusion protein vaccine
Vidprevtyn is a recombinant baculovirus vaccine and comprises of recombinant S-protein COVID-19 antigen expressed in Baculo virus expression system
Covidful is an inactivated vaccine composed of inactivated SARS-CoV-2 virus antigen
The vaccine is an inactivated whole virion vaccine composed of inactivated SARS-CoV-2 virus antigen
The vaccine is an inactivated vaccine composed of inactivated novel coronavirus antigen
Intranasal Covid19 vaccine developed by researchers at the University of Hong Kong (HKU) in collaboration with Xiamen University and Wantai pharmaceutical. It comprises of influenza virus vector expressing receptor binding domain (RBD) of corona virus surface antigen. It is being developed by replicating viral vector platform
SCTV01C is a new generation of bivalent mutant strain recombinant protein vaccine. The active ingredients of SCTV01C contain the recombinant S trimer protein antigens of the two major mutant strains identified by the WHO , Alpha ( Alpha ) and Beta ( Beta ), and adopt a new type of oil-in-water that can significantly enhance Th1 cells compared with traditional aluminum adjuvants
The vaccine candidate comprises of recombinant proteins produced from the insect cells and target spike protein receptor-binding domain (S-RBD) of SARS-CoV-2.
SCB-2019 comprises of recombinant, trimeric spike (S) protein of Wuhan Coronavirus and is being developed based on trimer-tag technology.
Soberana 02 comprises conjugated recombinant receptor-binding domain (RBD) of SARS-CoV-2 and an adjuvant.
Soberana Plus comprises of receptor-binding domain (RBD) of SARS-CoV-2 and an adjuvant.
SYS-6006 is a mRNA vaccine covering Omicron subvariant BA.5’s core mutation at the spike mutation positions.
ReCOV is a recombinant COVID-19 vaccine being developed by Jiangsu Recbio with its technology platforms including the novel adjuvant and protein engineering platforms, and the adjuvant used therein is the self-developed novel adjuvant BFA03.
Bimervax is a bivalent adjuvanted vaccine containing a recombinant protein based on the Beta and Alpha variants of SARS-CoV-2.
SCTV-01E is a COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine.
The vaccine candidate is a recombinant COVID-19 trivalent (XBB+BA.5+Delta) protein vaccine (Sf9 cell), produced from the insect cells and target spike protein receptor-binding domain (S-RBD) and HR proteins of SARS-CoV-2.
Gemcovac-OM is a mRNA-based Omicron-specific booster vaccine
DAICHIRONA for Intramuscular Injection is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus, utilizing a novel nucleic acid drug delivery system discovered by Daiichi Sankyo.
The vaccine candidate is an Omicron XBB.1.5-adapted monovalent COVID-19 vaccine tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and administered as a single dose
The vaccine candidate contains nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage XBB.1.5
The vaccine is a protein-based non-mRNA adjuvanted COVID vaccine composed of spike protein from the SARS-CoV-2 Omicron variant lineage XBB.1.5 (2023-2024 formula).
Convidecia Air based on adenovirus vector technological platform provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth.
Kostaive is a self-amplifying mRNA technology developed COVID 19 Vaccine. It is designed to self-amplify once delivered into cells, so that it generates a strong immune response and the potential for extended duration of protection.
The vaccine is a recombinant SARS-CoV-2 Beta variant fusion protein vaccine/recombinant SARS-CoV-2 delta variant fusion protein vaccine.
SYS6006.32 is a bivalent COVID-19 mRNA vaccine containing XBB.1.5 and BQ.1 variants with broad-spectrum cross-immune activity.
The vaccine is a mRNA vaccine designed for the full-length S protein antigen of the XBB.1.5 variant strain and is formulated as an injectable suspension
The vaccine comprises of egg-based, inactivated, whole chimeric Newcastle disease virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) with CpG 1018 as an adjuvant.
According to the World Health Organization (WHO), "Herd Immunity, also known as population immunity, is the indirect protection from an infectious disease that happens when a population is immune either through vaccination or immunity developed through previous infection."
Herd immunity against Covid-19 has been widely debated over the past months, however WHO has admitted, "we do not have a clear understanding of the herd immunity level for Covid-19."
In the context of Covid-19, herd immunity level is 60-70%,but could be higher if the new variants of the virus are more contagious.
The assumption should always be higher rather than lower with some recent research suggesting the number of the population that needed to be vaccinated ranged from 69-93%.
Eisai has lowered the sales forecast for its Alzheimer’s drug Leqembi (lecanemab), primarily citing delays in revenue in the US.…